Evidence map›Paper›PMID 39159003›Full record

ArticleThe oncologist2024

Treatment of Acute Myeloid Leukemia in the Community Setting.

Taha Al-Juhaishi, Servillano Dela Cruz, Rohan Gupta, Gina Keiffer, Vicki A Morrison, Iuliana Shapira, Ashley Woods, Kelly Norsworthy, Romeo Angelo de Claro, Marc R Theoret and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Time toxicity among patients with cancer: a scoping review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Taha Al-JuhaishiOklahoma Health Sciences Center, University of Oklahoma, Oklahoma City, OK, USA.ORCID 0000-0002-8359-0178
Servillano Dela CruzFlorida Cancer Specialists & Research Institute, Inverness, FL, USA.
Rohan GuptaThe Center for Cancer and Blood Disorders, Fort Worth, TX, USA.
Gina KeifferSidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.
Vicki A MorrisonHennepin County Medical Center, University of Minnesota, Minneapolis, MN, USA.
Iuliana ShapiraRegional Cancer Care Associates, Teaneck, NJ, USA.
Ashley WoodsCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Kelly NorsworthyCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Romeo Angelo de ClaroCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Marc R TheoretOncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring, MD, USA.
Ravin GargMaryland Oncology and Hematology, Annapolis, MD, USA.
Elizabeth Dianne PulteCenter for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment landscape for acute myeloid leukemia (AML) is rapidly changing. Many new agents and lower-intensity regimens have been approved and can be safely used by hematologists and oncologists in both academic and community settings. The US Food and Drug Administration (FDA) held a virtual symposium on AML treatment in the community in November 2022. Several members of the FDA, along with practicing hematologists and oncologists in both academic and community settings, participated in the symposium. The goal of the symposium was to discuss challenges and opportunities in the treatment of patients with AML in community oncology settings. A summary of these discussions and key considerations are presented here.

Indexed as

Leukemia, Myeloid, AcuteHumansUnited Statescommunity settinghematologic malignancyleukemiatreatment options

Identifiers

PMID39159003
PMCPMC11379644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.